Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon's Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03240991

Acronym

QUALANGIO

Enrollment

Registered

2017-08-07

Start date

2016-07-11

Completion date

2016-12-01

Last updated

2018-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angioedema

Keywords

bradykinin-mediated angiodema, quality of life

Brief summary

This study aims to describe quality of life in hereditary or acquired non drug-related bradykinin-mediated angioedema patients, using validated questionnaires

Interventions

OTHERQuality of life

Dermatology Life Quality Index, Angioedema Quality of Life Questionnaire, Angioedema Activity Score

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinically documented angioedema due to C1 inhibitor deficiency, hereditary (type I et II) or acquired * Clinically documented angioedema with normal C1 inhibitor activity (hereditary type III)

Exclusion criteria

* Acquired angioedema with normal C1 inhibitor activity (former drug-induced) * Minor subjects * Vulnerable subjects (under guardianship/curatorship/tutorship) * Pregnant women

Design outcomes

Primary

Measure	Time frame	Description
Dermatology Life Quality Index (DLQI)	6 months	Description of Quality of Life (QoL) using DLQI
Angioedema Quality of Life (AE-QoL) Questionnaire	6 months	Description of QoL using AE-QOL questionnnaire

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026